DSM-Firmenich Valuation

Is ZX6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZX6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€131.24
Fair Value
18.2% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: ZX6 (€107.35) is trading below our estimate of fair value (€131.24)

Significantly Below Fair Value: ZX6 is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZX6?

Key metric: As ZX6 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ZX6. This is calculated by dividing ZX6's market cap by their current earnings.
What is ZX6's PE Ratio?
PE Ratio113.3x
Earnings€250.00m
Market Cap€28.33b

Price to Earnings Ratio vs Peers

How does ZX6's PE Ratio compare to its peers?

The above table shows the PE ratio for ZX6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.6x
SY1 Symrise
35.6x14.4%€14.0b
EVK Evonik Industries
40.2x33.0%€9.2b
WCH Wacker Chemie
29.6x37.0%€3.7b
ACT AlzChem Group
13x12.6%€651.3m
ZX6 DSM-Firmenich
113.3x31.7%€28.3b

Price-To-Earnings vs Peers: ZX6 is expensive based on its Price-To-Earnings Ratio (113.3x) compared to the peer average (29.6x).


Price to Earnings Ratio vs Industry

How does ZX6's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ZX6 113.3xIndustry Avg. 18.5xNo. of Companies10PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ZX6 is expensive based on its Price-To-Earnings Ratio (113.3x) compared to the European Chemicals industry average (18.5x).


Price to Earnings Ratio vs Fair Ratio

What is ZX6's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZX6 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio113.3x
Fair PE Ratio35.5x

Price-To-Earnings vs Fair Ratio: ZX6 is expensive based on its Price-To-Earnings Ratio (113.3x) compared to the estimated Fair Price-To-Earnings Ratio (35.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZX6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€107.35
€127.20
+18.5%
10.5%€146.00€78.00n/a21
Feb ’26€98.76
€127.34
+28.9%
10.5%€146.00€78.00n/a21
Jan ’26€97.06
€127.91
+31.8%
11.1%€146.00€78.00n/a21
Dec ’25€103.65
€128.63
+24.1%
10.9%€146.00€78.00n/a21
Nov ’25€107.50
€129.69
+20.6%
11.4%€158.00€78.00n/a22
Oct ’25€121.30
€127.46
+5.1%
12.1%€158.00€78.00n/a22
Sep ’25€122.70
€126.78
+3.3%
12.0%€158.00€78.00n/a22
Aug ’25€118.05
€124.96
+5.9%
12.0%€158.00€78.00n/a22
Jul ’25€105.85
€122.92
+16.1%
12.7%€158.00€75.00n/a22
Jun ’25€105.35
€121.87
+15.7%
12.7%€158.00€75.00n/a22
May ’25€105.40
€119.49
+13.4%
13.3%€158.00€75.00n/a22
Apr ’25€105.40
€118.08
+12.0%
14.7%€158.00€70.00n/a22
Mar ’25€99.42
€118.26
+18.9%
15.0%€158.00€70.00n/a22
Feb ’25€97.56
€111.55
+14.3%
17.5%€158.00€70.00€98.7622
Jan ’25€91.96
€112.78
+22.6%
18.3%€158.00€70.00€97.0622
Dec ’24€85.02
€114.69
+34.9%
20.5%€182.00€70.00€103.6522
Nov ’24€85.00
€116.42
+37.0%
19.9%€182.00€70.00€107.5022
Oct ’24€80.80
€123.35
+52.7%
18.7%€182.00€80.00€121.3022
Sep ’24€85.02
€124.90
+46.9%
17.4%€182.00€80.00€122.7022
Aug ’24€98.34
€129.48
+31.7%
14.9%€175.00€88.00€118.0518
Jul ’24€99.18
€141.10
+42.3%
12.8%€175.00€114.00€105.8517
Jun ’24€101.45
€144.87
+42.8%
9.7%€175.00€126.00€105.3510
May ’24€116.80
€134.25
+14.9%
1.9%€137.00€130.00€105.404
Analyst Price Target
Consensus Narrative from 21 Analysts
€127.14
Fair Value
15.6% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 19:33
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DSM-Firmenich AG is covered by 57 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mutlu GundoganABN AMRO Bank N.V.
Martin SchneeAlphaValue
Volker BosseBaader Helvea Equity Research